Axon Enterprise, Inc. (NASDAQ:AXON) Short Interest Update

Axon Enterprise, Inc. (NASDAQ:AXON) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 2,420,000 shares, a decrease of 6.9% from the January 15th total of 2,600,000 shares. Based on an average daily trading volume, of 894,900 shares, the short-interest ratio is currently 2.7 days.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. JMP Securities increased their price objective on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 4th. Robert W. Baird increased their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. The Goldman Sachs Group raised their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research note on Monday, January 27th. TD Cowen initiated coverage on shares of Axon Enterprise in a research note on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price target on the stock. Finally, Northland Securities raised their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $542.15.

Axon Enterprise Stock Up 2.8 %

Shares of NASDAQ:AXON opened at $683.41 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The company has a market cap of $52.11 billion, a PE ratio of 176.59, a price-to-earnings-growth ratio of 6.79 and a beta of 1.05. Axon Enterprise has a 52 week low of $260.27 and a 52 week high of $698.67. The firm has a 50 day simple moving average of $623.22 and a 200 day simple moving average of $509.17.

Insider Buying and Selling at Axon Enterprise

In other news, insider Jeffrey C. Kunins sold 2,304 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $654.79, for a total value of $1,508,636.16. Following the sale, the insider now owns 128,542 shares in the company, valued at approximately $84,168,016.18. This represents a 1.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Joshua Isner sold 1,291 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $642.43, for a total transaction of $829,377.13. Following the sale, the president now owns 181,892 shares in the company, valued at approximately $116,852,877.56. This trade represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,711 shares of company stock valued at $5,631,561 in the last ninety days. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock worth $5,019,886,000 after buying an additional 275,959 shares in the last quarter. Geode Capital Management LLC lifted its position in Axon Enterprise by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock worth $1,095,542,000 after buying an additional 65,097 shares in the last quarter. Capital World Investors lifted its position in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock worth $1,079,145,000 after buying an additional 841,772 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in Axon Enterprise by 12.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after buying an additional 127,769 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after buying an additional 812,337 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.